Form 4: TriSalus Chief of Clinical Ops Sells Shares for Tax

TriSalus Life Sciences' Chief of Clinical Operations, Jodi Devlin, sold shares to cover tax obligations related to vested restricted stock units.

Summary

• Jodi Devlin, Chief of Clinical Operations at TriSalus Life Sciences, Inc. (TLSI), reported sales of common stock.
• The sales occurred on March 11, 2026, March 12, 2026, and March 16, 2026.
• A total of 3,207 shares were sold across these three transactions.
• The shares were sold at average prices of $4.13, $4.09, and $4.12, respectively.
• Following these transactions, Jodi Devlin beneficially owns 97,364 shares of common stock.
• The sales were explicitly stated to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units (RSUs).
• These transactions do not represent discretionary sales by the reporting person.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While shares were sold, it was a non-discretionary transaction for tax purposes following the vesting of RSUs, which implies the executive earned the shares.

Positives

• The underlying event, the vesting of restricted stock units, indicates that performance conditions (if any) were met, leading to the award of shares to the executive.

Negatives

• The direct beneficial ownership of common stock by the Chief of Clinical Operations decreased by 3,207 shares due to the sales.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The reported sales represent shares sold to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the reporting person.
• These transactions do not represent a discretionary sale by the reporting person.

Industry Context

StockSavvy.ai notes that sales of shares to cover tax withholding obligations upon the vesting of restricted stock units are a common and routine practice for executives receiving equity compensation. This type of transaction is generally not indicative of management's sentiment about the company's future prospects, unlike discretionary sales.

Stakeholder Impact

• Shareholders: The reduction in direct insider ownership is minimal and due to a non-discretionary event, thus unlikely to significantly impact shareholder confidence.
• Employees: The vesting of RSUs and subsequent tax-related sale is a standard part of executive compensation, reflecting the company's compensation practices.

Key Dates

Recommendation

The reported sales are non-discretionary, executed solely to cover tax obligations arising from the vesting of restricted stock units. This type of transaction does not reflect a change in the executive's investment conviction or the company's fundamentals, therefore, it does not warrant a change in investment recommendation.

Keywords

TriSalus Life Sciences, TLSI, Jodi Devlin, Insider Transaction, Form 4, Stock Sale, Tax Withholding, Restricted Stock Units, Executive Compensation